Cargando…

Dendritic cell-derived exosomes (Dex) are potential biomarkers of response to Ipilimumab in metastatic melanoma

Detalles Bibliográficos
Autores principales:	Stucci, Stefania, Tucci, Marco, Ascierto, Paolo Antonio, Passarelli, Anna, Mariaelena, Capone, Madonna, Gabriele, Ester, Simeone, Grimaldi, Antonio Maria, Silvestris, Franco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4315280/ http://dx.doi.org/10.1186/1479-5876-13-S1-P15

Ejemplares similares

Analysis of T and NK cells immune response in Ipilimumab treated Melanoma patients
por: Tallerico, Rossana, et al.
Publicado: (2015)

Systems biology analysis of immune signaling in peripheral blood mononuclear cells (PBMC) of melanoma patients receiving ipilimumab; basis for clinical response biomarker identification
por: Hotson, Drew, et al.
Publicado: (2013)

Systems biology analysis of immune signaling in peripheral blood mononuclear cells (PBMC) of melanoma patients receiving ipilimumab; basis for response biomarker identification
por: Hotson, Drew, et al.
Publicado: (2014)

MISIPI study: Melanoma ImmunoScore evaluation in patients treated with IPIlimumab
por: Bifulco, Carlo, et al.
Publicado: (2014)

Exosomal CD73 from serum of patients with melanoma suppresses lymphocyte functions and is associated with therapy resistance to anti-PD-1 agents
por: Turiello, Roberta, et al.
Publicado: (2022)

Automatic discovery of image-based signatures for ipilimumab response prediction in malignant melanoma
por: Harder, Nathalie, et al.
Publicado: (2019)

Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use
por: Ascierto, Paolo A, et al.
Publicado: (2012)

Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations
por: Ascierto, Paolo A., et al.
Publicado: (2019)

Exosomes in melanoma: a role in tumor progression, metastasis and impaired immune system activity
por: Tucci, Marco, et al.
Publicado: (2018)

Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy
por: Mozzillo, Nicola, et al.
Publicado: (2015)

Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab
por: Capone, Mariaelena, et al.
Publicado: (2018)

Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab
por: Morello, Silvana, et al.
Publicado: (2017)

Ipilimumab and Stereotactic Radiosurgery with CyberKnife(®) System in Melanoma Brain Metastases: A Retrospective Monoinstitutional Experience
por: Borzillo, Valentina, et al.
Publicado: (2021)

Immune System Evasion as Hallmark of Melanoma Progression: The Role of Dendritic Cells
por: Tucci, Marco, et al.
Publicado: (2019)

Circulating dendritic cell levels identify high-risk stage II-III melanoma patients: a potential role as additional prognostic marker
por: Stucci, Stefania, et al.
Publicado: (2015)

Serious haematological toxicity during and after ipilimumab treatment: a case series
por: Simeone, Ester, et al.
Publicado: (2014)

Combination therapy with ipilimumab and electrochemotherapy: preliminary efficacy results and correlation with immunological parameters
por: Simeone, Ester, et al.
Publicado: (2014)

Potential clinical implications of CD4(+)CD26(high) T cells for nivolumab treated melanoma patients
por: Galati, Domenico, et al.
Publicado: (2023)

Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy
por: Grimaldi, Antonio M, et al.
Publicado: (2014)

Melanoma-derived soluble mediators modulate neutrophil biological properties and the release of neutrophil extracellular traps
por: Modestino, Luca, et al.
Publicado: (2023)

Immune system and melanoma biology: a balance between immunosurveillance and immune escape
por: Passarelli, Anna, et al.
Publicado: (2017)

Clinical Categorization Algorithm (CLICAL) and Machine Learning Approach (SRF-CLICAL) to Predict Clinical Benefit to Immunotherapy in Metastatic Melanoma Patients: Real-World Evidence from the Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy
por: Madonna, Gabriele, et al.
Publicado: (2021)

A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation
por: Simeone, Ester, et al.
Publicado: (2021)

Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases
por: Queirolo, Paola, et al.
Publicado: (2014)

Vitiligo-specific soluble biomarkers as early indicators of response to immune checkpoint inhibitors in metastatic melanoma patients
por: Carbone, Maria Luigia, et al.
Publicado: (2022)

Immunoscore: a new possible approach for melanoma classification
por: Capone, Mariaelena, et al.
Publicado: (2014)

Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study
por: Queirolo, Paola, et al.
Publicado: (2017)

High expression of a spliced variant of FKBP51 in peripheral blood mononuclear cells of melanoma patients may be related to PDL-1 on tumour and predictive of response to Ipilimumab
por: Simeone, Ester, et al.
Publicado: (2014)

Corrigendum: Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study
por: Queirolo, Paola, et al.
Publicado: (2018)

Efficacy of radiotherapy in patients on progression after treatment with ipilimumab 3 mg/kg
por: Grimaldi, Antonio M, et al.
Publicado: (2014)

The Ratio of GrzB(+) − FoxP3(+) over CD3(+) T Cells as a Potential Predictor of Response to Nivolumab in Patients with Metastatic Melanoma
por: Scognamiglio, Giosuè, et al.
Publicado: (2021)

Could asymptomatic carriers spread the SARS-CoV-2 infection? Experience from the Italian second wave
por: Atripaldi, Luigi, et al.
Publicado: (2021)

Frequency of circulating CD8+CD73+T cells is associated with survival in nivolumab-treated melanoma patients
por: Capone, Mariaelena, et al.
Publicado: (2020)

PD-L1(+) neutrophils as novel biomarkers for stage IV melanoma patients treated with nivolumab
por: Cristinziano, Leonardo, et al.
Publicado: (2022)

Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian ipilimumab expanded access programme (EAP)
por: Ascierto, Paolo Antonio, et al.
Publicado: (2013)

The abscopal effect: efficacy of radiotherapy in patients on progression after treatment with ipilimumab 3 mg/kg
por: Grimaldi, Antonio M, et al.
Publicado: (2013)

The mechanisms of acute interstitial nephritis in the era of immune checkpoint inhibitors in melanoma
por: Marco, Tucci, et al.
Publicado: (2019)

Altered Frequencies and Functions of Innate Lymphoid Cells in Melanoma Patients Are Modulated by Immune Checkpoints Inhibitors
por: Cristiani, Costanza Maria, et al.
Publicado: (2022)

Tumor-derived exosomes promote the in vitro osteotropism of melanoma cells by activating the SDF-1/CXCR4/CXCR7 axis
por: Mannavola, Francesco, et al.
Publicado: (2019)

Immunotherapy in metastatic melanoma: a novel scenario of new toxicities and their management
por: Simeone, Ester, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_lbdj3rvd5v2ig5fh6aslc54e7r